Search - tctmd.com

Displaying 161 - 180 of 352

Sort: Relevancy | Date

News Daily News

BMS 再见？新 DAPT 分析显示 DES 支架血栓形成率较低

Yael L. Maxwell

October 26, 2015

Presentation TCT 2015

Cangrelor IV: Transitioning to Oral ADP Antagonists

Presenter: Deepak L. Bhatt, Robert A. Harrington, Harvey D. White

October 15, 2015

Presentation TCT 2015

Cangrelor III: Effects on Intraprocedural and Postprocedural Stent Thrombosis

Presenter: Deepak L. Bhatt, Robert A. Harrington, Harvey D. White, Philippe Généreux

October 15, 2015

Presentation TCT 2015

Cangrelor II: Perspectives on in Whom to Actually Use It

Presenter: Deepak L. Bhatt, Robert A. Harrington, Harvey D. White

October 15, 2015

Presentation TCT 2015

Cangrelor I: Data Essentials From the Champion Trials

Presenter: Deepak L. Bhatt, Robert A. Harrington, Harvey D. White

October 15, 2015

Presentation TCT 2015

The RE-DUAL PCI Trial (Dabigatran in Patients With ACS and Atrial Fibrillation): Design, Rationale, and Status

Presenter: Pascal Vranckx, Deepak L. Bhatt

October 14, 2015

Presentation TCT 2015

Identifying and Studying Data Gaps: DAPT Duration What's Settled, and What's Not?

Presenter: Deepak L. Bhatt, Martin Rose, John A. Bittl

October 14, 2015

Presentation TCT 2015

Identifying and Studying Data Gaps: Cangrelor Use What's Settled, and What's Not?

Presenter: Deepak L. Bhatt, Martin Rose, Gregg W. Stone

October 14, 2015

Presentation TCT 2015

TCT 83: Long-term (24-Month) Blood Pressure Results of Catheter-Based Renal Artery Denervation SYMPLICITY HTN-3 Randomized Controlled Trial

Presenter: Michael A. Weber, Stephen G. Worthley, Deepak L. Bhatt

October 13, 2015

Presentation TCT 2015

Debate: What Is the Optimal ADP-Antagonist Preloading Approach in STEMI? Cangrelor!

Presenter: Eric Boersma, E. Magnus Ohman, Deepak L. Bhatt

October 12, 2015

News Daily News

在PCI患者中切入部位和坎格雷洛之间没有相互作用

Caitlin E. Cox

October 06, 2015

News Daily News

No Interplay Between Access Site, Cangrelor Effects in PCI Patients

Caitlin E. Cox

October 06, 2015

News Daily News

No hay interacción entre el punto de acceso y los efectos del Cangrelor en pacientes con PCI

Caitlin E. Cox

October 06, 2015

News Daily News

La FDA Aprueba un Fármaco contra la Insuficiencia Cardíaca que Beneficia la Supervivenia

Todd Neale

July 13, 2015

News Daily News

FDA批准了一种具有生存优势的心力衰竭药物

Todd Neale

July 13, 2015

News Daily News

FDA Approves Heart Failure Drug That Comes With Survival Benefit

Todd Neale

July 13, 2015

News Daily News

在2项新的研究中均有挥之不去的PPI的潜在心血管风险

June 18, 2015

News Daily News

Possible Cardiovascular Risk of PPIs Lingers in 2 New Studies

June 18, 2015

News Daily News

El Posible Riesgo Cardiovascular de los IBP se Mantiene en 2 Nuevos Estudios

June 18, 2015

Presentation CCVVC 2015

Data for Recent Antiplatelets and Antithrombotics

Presenter: Deepak L. Bhatt

June 17, 2015

Advertisement

BMS 再见？新 DAPT 分析显示 DES 支架血栓形成率较低

Cangrelor IV: Transitioning to Oral ADP Antagonists

Cangrelor III: Effects on Intraprocedural and Postprocedural Stent Thrombosis

Cangrelor II: Perspectives on in Whom to Actually Use It

Cangrelor I: Data Essentials From the Champion Trials

The RE-DUAL PCI Trial (Dabigatran in Patients With ACS and Atrial Fibrillation): Design, Rationale, and Status

Identifying and Studying Data Gaps: DAPT Duration What's Settled, and What's Not?

Identifying and Studying Data Gaps: Cangrelor Use What's Settled, and What's Not?

TCT 83: Long-term (24-Month) Blood Pressure Results of Catheter-Based Renal Artery Denervation SYMPLICITY HTN-3 Randomized Controlled Trial

Debate: What Is the Optimal ADP-Antagonist Preloading Approach in STEMI? Cangrelor!

在PCI患者中切入部位和坎格雷洛之间没有相互作用

No Interplay Between Access Site, Cangrelor Effects in PCI Patients

No hay interacción entre el punto de acceso y los efectos del Cangrelor en pacientes con PCI

La FDA Aprueba un Fármaco contra la Insuficiencia Cardíaca que Beneficia la Supervivenia

FDA批准了一种具有生存优势的心力衰竭药物

FDA Approves Heart Failure Drug That Comes With Survival Benefit

在2项新的研究中均有挥之不去的PPI的潜在心血管风险

Possible Cardiovascular Risk of PPIs Lingers in 2 New Studies

El Posible Riesgo Cardiovascular de los IBP se Mantiene en 2 Nuevos Estudios

Data for Recent Antiplatelets and Antithrombotics

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content